Synopsis:

Amy Burroughs, CEO of Terns Pharmaceuticals, joins Alok Tayi to share how she’s leading bold innovation in CML and obesity treatment, driving two high-stakes data readouts in 2025. From a non-linear path through tech, brand management, and Genentech to building resilient biotech teams, Amy reveals why product positioning, tolerability, and mentorship matter just as much as the science. She also shares her take on CEO loneliness, the value of a “personal board of directors,” and what it takes to lead with clarity, grit, and purpose in today’s biotech landscape.

Biography:

Amy Burroughs joined as our Chief Executive Officer and a member of our Board of Directors in February 2024, bringing more than 25 years of leadership experience. Most recently, she served as CEO at Cleave Therapeutics, where she led the company through financings, spearheaded licensing and collaboration deals, and oversaw the clinical development of its investigational therapy, CB-5339, for the treatment of acute myeloid leukemia. Previously, she served as executive in residence at 5AM Ventures and, in parallel, as senior advisor to one of its portfolio companies, Crinetics Pharmaceuticals, during its initial public offering. Earlier in her career, Ms. Burroughs held roles of increasing responsibility in commercial and strategy at Genentech, commercial and business development at other high growth therapeutics companies, talent and governance at Egon Zehnder International, and brand management at Procter & Gamble. Ms. Burroughs earned her M.B.A. from Harvard Business School, where she graduated as a Baker Scholar, and her B.A. in computer science with a minor in economics from Dartmouth College. She is currently a member of the board and audit committees at Tenaya Therapeutics.

Synopsis:

Host Rahul Chaturvedi sits down with Jeremy Bender, CEO of Day One Biopharmaceuticals, to explore the bold mission of transforming pediatric oncology. From earning FDA approval for a groundbreaking brain cancer drug to building a culture rooted in execution and empathy, Jeremy shares lessons from big pharma and startups alike. He discusses how to lead through uncertainty, scale with discipline, and stay focused on delivering targeted therapies for underserved patients. They also dive into real-world data, AI’s emerging role in clinical trial design, and why pediatric-first innovation could reshape the future of oncology.

Biography:

Jeremy Bender, Ph.D., M.B.A. has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020.

Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012.

Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. He started his career in the life sciences practice at Boston Consulting Group, a management consulting company.

Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

Synopsis:

What do courtroom litigation, computational biology, and fibrosis drug development have in common? In this episode of Biotech 2050, host Alok Tayi speaks with Ahmed Mousa, CEO of Vicore Pharma, to explore his unconventional journey from biotech law to the C-suite. Ahmed shares how Vicore is advancing a first-in-class therapy targeting the angiotensin II type 2 receptor to treat idiopathic pulmonary fibrosis (IPF)—a devastating disease with limited options and poor survival. The conversation dives into how AI is reshaping drug discovery, the promise of precision in early-stage candidate design, and the regulatory and data challenges biotech must overcome. Ahmed also reflects on leading a Swedish-listed biotech as an American CEO, and how a patient-first mission continues to fuel bold innovation across continents.

Biography:

Ahmed Mousa is the Chief Executive Officer of Vicore Pharma (VICO.ST), where he leads the company’s mission to advance angiotensin II type 2 receptor agonists for the treatment of idiopathic pulmonary fibrosis and other serious diseases. Under his leadership, Vicore continues to expand its clinical pipeline and global presence in respiratory and fibrotic diseases.

Previously, Ahmed served as Senior Vice President, Chief Business Officer, and General Counsel at Pieris Pharmaceuticals (PIRS). In this role, he was the site head for the company’s Boston office and oversaw business development, portfolio strategy, centralized project leadership, and quality assurance. He also led Pieris’ legal and intellectual property functions, including licensing, corporate governance, and management of the company’s global patent portfolio.

Before joining Pieris, Ahmed was an attorney at Covington & Burling LLP, where he advised pharmaceutical and biotechnology companies on a range of regulatory and intellectual property matters. He also served as a law clerk for the U.S. Court of Appeals for the Third Circuit and began his legal career as an IP associate at Kirkland & Ellis LLP.

Ahmed holds dual undergraduate degrees in Molecular Biology and Government from Cornell University, a Master’s in Biotechnology from Johns Hopkins University, and a J.D. with honors from Georgetown Law, where he was Editor-in-Chief of the Georgetown Journal of International Law.

Synopsis:

When an introverted engineer becomes the President & CEO of REGENXBIO, transformation follows. Curran Simpson joins host Rahul Chaturvedi to unpack his unlikely journey from biotech operations to the C-suite—and how that hands-on experience is reshaping gene therapy's future.

They dive into the evolution of REGENXBIO’s pipeline, tackling ultra-rare diseases like MPS II, ambitious plans for Duchenne Muscular Dystrophy, and commercial partnerships with giants like AbbVie. Curran offers hard-earned leadership lessons, honest reflections on scaling science, and insights into how one-time gene therapies could revolutionize treatment in both rare and common diseases.

From clinical nuance to strategic boldness, this is a masterclass in biotech leadership, platform focus, and staying patient-first—no matter how complex the science or market.

Biography:

Curran M. Simpson is the President and Chief Executive Officer and member of the Board of Directors at REGENXBIO. Mr. Simpson previously served as the Company’s Chief Operating Officer. In that role, he led key business functions including Research & Clinical Development, Corporate Strategy, Manufacturing & Quality, Regulatory, and Commercial Operations. Mr. Simpson joined REGENXBIO in 2015 with extensive leadership experience across biopharmaceutical operations and served as the Company’s Chief Technology and Operations Officer before becoming COO. Prior to joining REGENXBIO, he was the Regional Supply Chain Head for North America and Interim Chief Operating Officer at GlaxoSmithKline (GSK). Mr. Simpson earlier served as interim CEO of Human Genome Sciences (HGS), where he led the integration of HGS into GSK, and as Senior Vice President of Operations and Vice President of Manufacturing Operations at HGS. Prior to HGS, Mr. Simpson was Director of Manufacturing Sciences at Biogen. Earlier in his career, Mr. Simpson served in an overseas assignment at Novo-Nordisk Biochem in Denmark and in various senior development and engineer roles at Genentech, working on Herceptin and Avastin, among other roles. Mr. Simpson has an M.S. in surface and colloid science from Clarkson University and a B.S. in chemistry from the Clarkson College of Technology.

Synopsis:

Longevity isn’t just about living longer—it’s about living better. In this insightful episode of Biotech 2050, host Alok Tayi sits down with Sergey Jakimov, Founding Partner at LongeVC, to unpack what it really takes to invest in the future of healthspan.

Blending his experience as a medtech entrepreneur, rare disease patient, and venture capitalist, Sergey shares why LongeVC focuses on practical, science-backed longevity solutions rather than hype-driven moonshots. He explains why aging isn’t a disease, how diagnostics differ from therapeutics in venture ROI, and what makes AI drug discovery a pivotal unlock in modern biotech.

The conversation also explores the rise of pet longevity, the role of lifestyle in aging, and how LongeVC grew from a €20M experiment to a high-performing fund now raising $250M for Fund Two—all with zero write-offs.

For founders, funders, and anyone curious about the intersection of biotech, aging, and real-world outcomes, this episode offers an honest, no-fluff look at building the future of longevity—one evidence-based investment at a time.

Biography:

Sergey Jakimov is a founding partner of LongeVC, a venture capital fund supporting early-stage biotech and longevity-focused founders that are changing the world. He is a serial entrepreneur, having co-founded 3 deep-tech ventures and raised more than $40 million in venture funding for his own ventures and as an entrepreneur in residence. He has worked with several other early-stage companies in the therapeutics space on fundraising, IP protection, and clinical trial strategies, focusing on early treatments in cardiovascular, oncology, and neurodegenerative spaces. He is also a visiting lecturer to several universities on venture capital and intellectual property rights, and he co-authored a master's program in Technology Law for the Riga Graduate School of Law.

Since 2018, he has co-founded medical tech startup Longenesis, a cutting-edge company that unlocks the hidden value of biomedical data and accelerates novel drug treatment & discovery. In 2020 he co-founded LongeVC, and in 2021, he co-founded the Longevity Science Foundation - a non-profit organization advancing the field of human longevity by funding research and development of medical technologies to extend the healthy human lifespan.

He holds a BSc in International Affairs from Rīga Stradiņš University and two MScs in Political Science and Government and Law and Finance from Central European University and Riga Graduate School of Law, respectively. He was named Forbes Latvia 30 Under 30 in technology and healthcare in 2020.

Synopsis:

What happens when a world-class scientist and a philanthropic legacy collide with one of medicine’s greatest challenges? Dr. Howard Fillit and Mark Roithmayr of the Alzheimer’s Drug Discovery Foundation (ADDF) join host Alok Tayi for an inspiring conversation on bold science, visionary funding models, and the future of Alzheimer’s research. From treating Estée Lauder in the 1990s to building a $100M venture philanthropy engine, they trace ADDF’s evolution into a global leader in high-risk, high-reward drug development. The discussion covers the rise of biomarkers and digital diagnostics, the foundation’s partnerships with visionaries like Bill Gates and Jeff Bezos, and how ADDF’s venture philanthropy approach bridges the “valley of death” in biotech. They also dive into global regulatory challenges, the economic urgency of Alzheimer’s, and why the future lies in prevention, precision medicine, and a patient-first mindset. This episode is a masterclass in scientific grit, ecosystem thinking, and turning urgency into progress.

Biography:

Howard Fillit, MD

Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation

Howard Fillit, MD, is a geriatrician, neuroscientist, and innovative philanthropy executive, who has led the Alzheimer’s Drug Discovery Foundation (ADDF) since its founding. Dr. Fillit has held faculty positions at The Rockefeller University, the SUNY-Stony Brook School of Medicine and the Cornell University School of Medicine. In 1987, he joined the Mount Sinai School of Medicine, where he is a clinical professor of geriatric medicine and palliative care, medicine and neuroscience. Dr. Fillit also maintains a limited private practice in consultative geriatric medicine with a focus on Alzheimer's disease and related dementias.

He has authored or co-authored more than 300 publications and is the senior editor of Brocklehurst's Textbook of Geriatric Medicine and Gerontology. Dr. Fillit is the recipient of many awards and honors including the Rita Hayworth Award from the Alzheimer's Association.

Mark Roithmayr

Chief Executive Officer

Mark Roithmayr is an admired nonprofit leader with four decades of experience in both start-ups and mature organizations. As CEO of the ADDF, he is responsible for steering the Foundation’s overall strategy, focus, and business operations. Since joining the ADDF in 2017, the organization has transformed dramatically in impact, scale, presence, and brand. Under his leadership, the ADDF’s revenue has increased five-fold from $17M to over $90M, and mission-related investing has grown over 100%.

He works closely with Dr. Fillit, executive leadership, and the board to advance the ADDF’s mission of accelerating the discovery of drugs to prevent, treat, and cure Alzheimer’s disease and related dementias. His key accomplishments include securing donations from Bill Gates, Jeff Bezos, and MacKenzie Scott, and a 10-figure gift from the Lauder family to cover ADDF’s overhead for the next 20 years.

Synopsis:

What does bold biotech leadership look like in 2025?

In this episode of Biotech 2050, host Alok Tayi sits down with Stacy Lindborg, President & CEO of Imunon, to discuss bold innovation in ovarian cancer treatment and how harnessing the immune system through targeted gene therapy is reshaping survival outcomes.

Stacy shares insights from her 30-year career—from her statistical roots at Eli Lilly to her mission-driven leadership at Imunon. She highlights the groundbreaking results from Imunon’s IL-12 plasmid platform, which is showing a remarkable 13-month overall survival advantage in ovarian cancer patients and is now entering Phase 3 trials.

They also discuss the evolving biotech landscape, how adaptive trial designs and AI are unlocking clinical potential, and why cultivating a bold, transparent company culture is key to advancing transformational science.

Biography:

Stacy R. Lindborg, PhD, was appointed President and Chief Executive Officer of Imunon in May 2024. Dr. Lindborg has served on Imunon’s Board of Directors since June 2021. Dr. Lindborg has nearly 30 years of pharmaceutical and biotech industry experience with a particular focus on R&D, regulatory affairs, executive management and strategy development. She has designed, hired and led global teams, guiding long-term vision for growth through analytics and stimulating innovative development platforms to increase productivity. Prior to joining Imunon, Dr. Lindborg was Executive Vice President and Co-Chief Executive Officer at BrainStorm Cell Therapeutics where she will remain a member of the company’s Board of Directors. At BrainStorm she was accountable for creating and executing clinical development strategies through registration and launch and progressed its novel cell therapy for ALS through a positive Phase 3 Special Protocol Assessment (SPA) study with the U.S. Food and Drug Administration. She interacted frequently with investors and analysts, represented the company in the scientific community as well as with the media, and played an active role in discussions with potential business partners.

Dr. Lindborg previously was Vice President & Global Analytics and Data Sciences Head, responsible for R&D and marketed products at Biogen. She began her biopharmaceutical career at Eli Lilly and Company where over the course of 16 years she assumed positions of increasing responsibility, including Head of R&D strategy.

Dr. Lindborg received an M.A. and Ph.D. in statistics, and a B.A. in psychology and math from Baylor University. She has authored more than 200 presentations and 90 manuscripts that have been published in peer-reviewed journals, including 20 first-authored. She has held numerous positions within the International Biometric Society and American Statistical Association and was elected Fellow in 2008.

Synopsis:

What happens when a former journalist becomes one of biotech’s boldest investors? Meet Stephanie Sirota, Chief Business Officer and Partner at RTW Investments, who helped grow the firm from $27 million in assets to a global biotech force. In this engaging conversation with host Rahul Chaturvedi, Stephanie shares her unconventional path into the industry, and how a mission-driven, science-led investment strategy has guided RTW’s approach across public markets, private deals, and company creation.

Stephanie reflects on the evolution of biotech financing, why GLP-1 drugs are just getting started, and how RTW is preparing for changes in U.S. healthcare policy. She also unpacks how the firm sources opportunities, evaluates risk, and sticks to long-term conviction even in volatile markets. For Stephanie, great biotech investing starts with deep research, strong science, and a relentless focus on patient outcomes.

Whether you're an investor, operator, or simply curious about the future of medicine, this conversation is packed with insights on building bold bets—and the staying power behind them.

Biography:

Stephanie leads a team at RTW overseeing business development, strategic partnerships, communications, and investor relations.

Her background in investment banking and expertise in financial markets has helped position the firm as both a partner to life sciences companies and a steward of investors’ capital. Stephanie also manages RTW’s relationships with key partners including banks, academic institutions, corporations, investors, and NGOs. She has led the firm’s entry into the UK and European markets and serves as a director of the RTW Biotech Opportunities Ltd, a publicly traded investment fund listed on the London Stock Exchange.

Prior to joining RTW, she served as director at Valhalla Capital Advisors, a macro and commodity investment manager. Stephanie also worked in the New York and London offices of Lehman Brothers, where she advised on various Merger & Acquisitions, IPOs, and capital market financing transactions with a focus on cross-border transactions for the firm’s global corporate clients.

Stephanie graduated with honors from Columbia University and also received a Master’s Degree from the Columbia Graduate School of Journalism.

She serves as president of the RTW Foundation; and co-chair of Council of the New York Philharmonic.

Synopsis:

Building in biotech isn’t for the faint of heart—especially during a market downturn.

But that’s exactly when Steve Tregay, Managing Partner at Mission BioCapital, thrives. A seasoned entrepreneur and founder of Forma Therapeutics, Steven has navigated biotech’s toughest cycles—and emerged stronger each time.

Hosted by Rahul Chaturvedi, this conversation dives into what it really takes to launch and scale biotech companies: from mastering the evolution of the CEO role to raising nearly $900M through strategic partnerships, to knowing when it’s time to pass the torch.

Steve also shares how Mission BioCapital is rewriting the playbook for early-stage innovation through its Platinum Program, offering $500K and lab access to science founders ready to launch bold new ideas.

Real talk, real strategies, and a blueprint for building lasting biotech companies—especially when its hardest.

Biography:

Steve Tregay, PhD is a Managing General Partner based in our Cambridge office. He focuses on new therapeutics investments with a particular emphasis on company creation opportunities as well as on overall management of the firm. Within the Mission BioCapital portfolio, he is currently founding CEO and board member of Arclight Therapeutics, LLC, a founding board member at Jupiter BioVentures LLC, and has board roles at Vedere Bio and Nocion Therapeutics. In addition, Steve serves as Chairman of the Board of Directors at LabCentral. He is a Harvard Blavatnik Biomedical Accelerator Advisory Committee member and is a member of the board of advisors for the non-profit Life Sciences Cares.

Previously, Steve was the Founder and CEO of FORMA Therapeutics. Additional roles held prior to his engagement at FORMA include Managing Director for the Novartis Venture Fund and Executive Director & Head of Strategic Alliances for Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. Prior to Novartis, he held roles in research and business development at Array BioPharma.

Steve received his doctoral and Master’s degrees in organic chemistry from Harvard University and a Bachelor’s from Davidson College.

Synopsis:

In this episode of Biotech2050, host Rahul Chaturvedi sits down with Neil F. McFarlane, President and CEO of Zevra Therapeutics, to explore his unique leadership journey from military nurse to biotech executive. Neil shares reflections from his time at Genzyme and UCB, insights on running a rare disease-focused biotech, and the art of mission-driven leadership. He dives into Zevra’s recent therapeutic milestones, regulatory strategies, and the importance of reflection in high-stakes environments. This conversation offers powerful takeaways for anyone navigating biotech leadership, board management, or rare disease innovation.

Biography:

Neil F. McFarlane took the reins as President and CEO of Zevra Therapeutics, a commercial-stage rare disease therapeutics company, in October 2023, bringing with him a wealth of experience in the biopharma industry and specific expertise in neurological and rare diseases. Before joining Zevra, he served on the board of Collegium Pharmaceutical Inc. from 2022 to 2024 and was the CEO of Adamas Pharmaceuticals, Inc., a biopharmaceutical company developing treatments for neurological diseases, from 2019 until its acquisition by Supernus Pharmaceuticals in 2021.

Prior to Adamas, Mr. McFarlane was Chief Operating Officer at Retrophin, Inc. (now Travere Therapeutics, Inc.), from 2016 to 2019, where he managed day-to-day operations. He also held roles of increasing responsibility at UCB, Inc., Genzyme Corporation (now Sanofi), and Sangstat Medical Corporation, which was acquired by Genzyme.